PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-9.73%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
-11.29%
Cost reduction while VET shows 12.42% growth. Joel Greenblatt would examine competitive advantage.
-8.23%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
1.66%
Margin expansion while VET shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.76%
Other expenses reduction while VET shows 0.00% growth. Joel Greenblatt would examine efficiency.
12.80%
Operating expenses growth less than half of VET's 41.73%. David Dodd would verify sustainability.
-1.72%
Total costs reduction while VET shows 32.32% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-5.86%
D&A reduction while VET shows 8.51% growth. Joel Greenblatt would examine efficiency.
17.56%
EBITDA growth while VET declines. John Neff would investigate advantages.
-39.90%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-44.22%
Both companies show declining income. Martin Whitman would check industry conditions.
-38.21%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-152.54%
Other expenses reduction while VET shows 31.14% growth. Joel Greenblatt would examine advantage.
20.30%
Pre-tax income growth while VET declines. John Neff would investigate advantages.
33.26%
Pre-tax margin growth while VET declines. John Neff would investigate advantages.
-45.10%
Both companies reducing tax expense. Martin Whitman would check patterns.
56.92%
Net income growth while VET declines. John Neff would investigate advantages.
73.83%
Net margin growth while VET declines. John Neff would investigate advantages.
58.82%
EPS growth while VET declines. John Neff would investigate advantages.
55.15%
Diluted EPS growth while VET declines. John Neff would investigate advantages.
0.30%
Share count reduction below 50% of VET's 0.60%. Michael Burry would check for concerns.
0.15%
Diluted share reduction exceeding 1.5x VET's 0.46%. David Dodd would verify capital allocation.